Abstract

Research Article

Atherogenic risk assessment of naive HIV-infected patients attending Infectious Diseases Service of Kinshasa University Teaching Hospital, Democratic Republic of the Congo (DRC)

MMK Mbula*, HNT Situakibanza, GL Mananga, B Longo Mbenza, JRR Makulo, MM Longokolo, MN Mandina, NN Mayasi, MM Mbula, B Bepouka, GL Mvumbi, EN Amaela, DN Tshilumba, O Odio, BM Ekila, A Nkodila and BT Buasa

Published: 13 October, 2020 | Volume 3 - Issue 1 | Pages: 040-048

Background and aim: Metabolic abnormalities are common in HIV/AIDS. Increasingly, lipid ratios are used as screening tools for dyslipidaemia in these medical conditions. The aim of this study was to assess the ability of 4 lipid ratios to predict cardiovascular risks.

Methods: This is a cross-sectional and analytical study included 105 HIV+ patients followed in Kinshasa University Teaching Hospital (KUTH). Four indices [Atherogenic Index of Plasma (AIP), Castelli Risk Index (CRI) I and II, Atherogenic coefficient (AC)] were compared. Statistical analyzis consisted of measuring frequencies and means, Student’s t-tests, ANOVA and Ficher’s exact test, and the calculation of the Kappa value.

Results: Lipid ratios predicted respectively the risk in 62% (AIP), 28.6% (CRI-I) and 23.8% (CRI-II). CRI-I and II were elevated, especially in women. The AIP appeared to be a better predictor than CRI-I and II to assess dyslipidaemia in general and the high-risk frequency. The cholesterol detected risk in 66.7% (Low HDL-C), 50% (High LDL-C), 38.9% (High TC and/or TG).

The atherogenic risk was higher with age, advanced WHO stage, HIV-TB, HBV-HCV co-infections, smoking and alcohol intake. Haemoglobin (Hb) and CD4 counts were low when the risk was high. Age ≥ 50 years, stage 4 (WHO), CD4s+ ≤ 200 cells/µL were independent factors associated with atherogenic risk.

Conclusion: Lipid ratios can be used as reliable tools for assessing cardiovascular risk of naïve HIV-infected patients who received HAART.

Read Full Article HTML DOI: 10.29328/journal.ijcmbt.1001015 Cite this Article Read Full Article PDF

Keywords:

HIV; Cardiovascular risks Assessment; Lipid ratios; Kinshasa; DRCongo

References

  1. Deeks S, Lewin SR, Havlir DV. The end of AIDS infection as a chronic disease. The Lancet. 2013; 382: 1525-1533. PubMed: https://pubmed.ncbi.nlm.nih.gov/24152939/
  2. Serrano-Villar S, Gutiérrez F, Miralles C, Berenguer J, Rivero A, et al. Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infect Dis. 2016; 3: 097. PubMed: https://pubmed.ncbi.nlm.nih.gov/27419169/
  3. Pirillo A, Catapano AL, Norata GD. HDL in Infectious Diseases and Sepsis. In: von Eckardstein A., Kardassis D. (eds) High Density Lipoproteins. Handbook of Experimental Pharmacology. 2015; 224: 483-508. PubMed: https://pubmed.ncbi.nlm.nih.gov/25522999/
  4. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. [Updated 2019 Jan 8]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PubMed: https://www.ncbi.nlm.nih.gov/books/NBK326741/
  5. Reis RP. Cardiovascular Risk in HIV-infected patient. Rev Port Cardiol. 2019; 38: 471- 472. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964878/
  6. Currier JS, Hsue PY. The Role of Inflammation in HIV-Associated Atherosclerosis—One Size May Not Fit All. J Infect Dis. 2020; 221: 495-497. PubMed: https://pubmed.ncbi.nlm.nih.gov/31077267/
  7. Abutaleb A, Feinstein MJ. Coranary Artery Disease in HIV. 2020. https://www.acc.org/latest-in-cardiology/articles/2018/01/18/08/57/coronary-artery-disease-in-hiv
  8. Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nature Rev Cardiol. 2019; 16: 745–759. PubMed: https://pubmed.ncbi.nlm.nih.gov/31182833/
  9. Seecheran VK, Giddings SL, Seecheran NA. Acute coronary syndromes in patients with HIV. Coronary Artery Disease. 2017; 28: 166-172. PubMed: https://pubmed.ncbi.nlm.nih.gov/27845996/
  10. Raposo MA, Armiliato GN, Guimarães NS, Caram CA, Silveira RD, et al. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev. Soc. Bras. Med. Trop. 2017 50: 598-606. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000500598&lng=en
  11. Kumar S, Dhanawal. Central obesity & dyslipidemia in HIV patients on antiretroviral therapy. Indian J Med Res. 2018; 148: 366–368. PubMed: https://pubmed.ncbi.nlm.nih.gov/30665998/
  12. Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015; 2: e000174. PubMed: https://pubmed.ncbi.nlm.nih.gov/25815207/
  13. Policarpo S, Rodrigues T, Moreira AC, Valadas E. Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. Rev Port Cardiol. 2019; 38: 463-470. PubMed: https://pubmed.ncbi.nlm.nih.gov/31522936/
  14. Touloumi G, Kalpourtzi N, Papastamopoulos V, et al. Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. PLoS One. 2020; 15: e0230730. PubMed: https://pubmed.ncbi.nlm.nih.gov/32226048/
  15. Krikke M, Hoogeveen RC, Hoepelman AI, Visseren FL, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Medicine. 2016; 17: 289-297. PubMed: https://pubmed.ncbi.nlm.nih.gov/26268806/
  16. Bittencourt MS. Estimating Cardiovascular risk in HIV-Infected Patients. Arq Bras Cardiol. 2020; 114: 76–77. PubMed: https://pubmed.ncbi.nlm.nih.gov/32049173/
  17. Silva AG, Paulo RV, Silva-Vergara ML. Subclinical Carotid Atherosclerosis and Reduced DAD Score for Cardiovascular Risk Stratification in HIV-Positive Patients. Arq Bras Cardiol. 2020; 114: 68-75. PubMed: https://pubmed.ncbi.nlm.nih.gov/31664317
  18. Schoepf IC, Buechel RR, Kovari H, Hammoud DA, Tarr PE. Subclinical Atherosclerosis Imaging in People Living with HIV. J Clin Med. 2019; 8: 1125. PubMed: https://pubmed.ncbi.nlm.nih.gov/31362391/
  19. Hanna DB, Guo M, žková PB, et al. HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative. Clin Infect Dis. 2016; 63: 249–256. PubMed: https://pubmed.ncbi.nlm.nih.gov/27118787/
  20. Osegbe D, Soriyan OO, Ogbenna AA, Okpara HC, Azinge EC. Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital Ifeyinwa. Pan African Med J. 2016; 23: 206. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907765/
  21. Noumegni SR, Nansseu JR, Bigna JJ, et al. Atherogenic index of plasma and 10-year risk of cardiovascular disease in adult Africans living with HIV infection: A cross-sectional study from Yaoundé, Cameroon. JRSM Cardiovasc Dis. 2017; 6: 2048004017740478. PubMed: https://pubmed.ncbi.nlm.nih.gov/29435266/
  22. Onyedum CC, Young EE, Iroezindu MO, Chukwuka CJ, Nwagha UI. Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. Indian J Endocrinol Metab. 2014; 18: 631-636. PubMed: https://pubmed.ncbi.nlm.nih.gov/25285278/
  23. Adedokun AK, Olisekodiaka MJ, Adeyeye DA, et al. Castelli Risk Index, Atherogenic Index of Plasma, and Atherogenic Coefficient: Emerging Risk Predictors of Cardiovascular Disease in HIV-Treated Patients. Int J Clin Trials Case Stud. 2017; 2: 8-15.
  24. Noumegni, SR, Ama VJM, Assah, FK. et al. Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection: a cross-sectional study. Trop Dis Travel Med Vaccines. 2017; 3: 12. PubMed: https://pubmed.ncbi.nlm.nih.gov/28883982/
  25. Mbula MMK, Situakibanza HNT, Lelo GM, Mbenza bl, Makulo JRR, et al. Lipid profile of antiretroviral therapy-naive HIV-infected patients attending infectious diseases service of University Teaching Hospital of Kinshasa, Democratic Republic of the Congo (DRC). Int J Clin Virol. 2020; 4: 102-108. https://www.heighpubs.org/hjcv/ijcv-aid1023.php
  26. Bekolo CE, Nguena MB, Ewane L, Bekoule PS, Kollo B. The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population. BMC Public Health. 2014; 14: 236. PubMed: https://pubmed.ncbi.nlm.nih.gov/24606888/
  27. Singh M, Pathak MS, Paul A. A Study on Atherogenic Indices of Pregnancy Induced Hypertension Patients as Compared to Normal Pregnant Women. J Clin Diagn Res. 2015; 9: BC05-BC8. PubMed: https://pubmed.ncbi.nlm.nih.gov/26393117/
  28. Nimmanapalli HD, Kasi AD, Devapatla PK, Nuttakki V. Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus. Int J Res Med Sci. 2016; 4: 2863-2869.
  29. Bo MS, Cheah WL, Lwin S, New TM, Win TT, Aung M. Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia. J Nutrit Metabol. 2018; Article ID 7027624; 6.
  30. Sujatha R, Kavitha S. Atherogenic indices in stroke patients: A retrospective study. Iran J Neurol. 2017; 16: 78-82. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526781/
  31. Olamoyegun MA, Oluyombo R, Asaolu SO. Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria. Ann Afr Med. 2016; 15: 194–199. PubMed: https://pubmed.ncbi.nlm.nih.gov/27853034/
  32. HIV info.NIH.gov. HIV and older people. 2020. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-older-people

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

  • Immunological background for treatments with biologicals in CRSwNP
    L Klimek*, J Hagemann, I Casper, T Huppertz, A Bedbrook and J Bousquet L Klimek*,J Hagemann,I Casper,T Huppertz,A Bedbrook,J Bousquet. Immunological background for treatments with biologicals in CRSwNP. Arch Asthma Allergy Immunol. 2021: doi: 10.29328/journal.aaai.1001026; 5: 022-029
  • The Bacteriological Profile of Nosocomial Infections at the Army Central Hospital of Brazzaville
    Medard Amona*, Yolande Voumbo Matoumona Mavoungou, Hama Nemet Ondzotto, Benjamin Kokolo, Armel Itoua, Gilius Axel Aloumba and Pascal Ibata Medard Amona*,Yolande Voumbo Matoumona Mavoungou,Hama Nemet Ondzotto,Benjamin Kokolo,Armel Itoua,Gilius Axel Aloumba,Pascal Ibata. The Bacteriological Profile of Nosocomial Infections at the Army Central Hospital of Brazzaville. Int J Clin Microbiol Biochem Technol. 2025: doi: 10.29328/journal.ijcmbt.1001032; 8: 009-022
  • Nasal cytology in patients with previous SARS-CoV-2 infection: occurrence of atypical lymphocytes
    Arturo Armone Caruso*, Anna Miglietta, Giovanni De Rossi, Liliana Nappi, Veronica Viola, Stefano De Rossi, Salvatore Del Prete, Clara Imperatore, Sabato Leo, Daniele Naviglio, Monica Gallo, Daniela Marasco and Lucia Grumetto Arturo Armone Caruso*, Anna Miglietta, Giovanni De Rossi, Liliana Nappi, Veronica Viola, Stefano De Rossi, Salvatore Del Prete, Clara Imperatore, Sabato Leo, Daniele Naviglio, Monica Gallo, Daniela Marasco, Lucia Grumetto. Nasal cytology in patients with previous SARS-CoV-2 infection: occurrence of atypical lymphocytes. Adv Treat ENT Disord. 2023: doi: 10.29328/journal.ated.1001014; 7: 001-006
  • Vestibular-limbic relationships: Brain mapping
    Paolo Gamba* Paolo Gamba*. Vestibular-limbic relationships: Brain mapping. Insights Depress Anxiety. 2018: doi: 10.29328/journal.ida.1001006; 2: 007-013
  • May we feed cancer?
    Maria Grazia Spurio* Maria Grazia Spurio*. May we feed cancer?. Insights Depress Anxiety. 2018: doi: 10.29328/journal.ida.1001005; 2: 001-006

Read More

Most Viewed

Read More

Help ?